SOR-C13

General Information


DRACP ID  DRACP02006

Peptide Name   SOR-C13

Sequence  KEFLHPSKVDLPR

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Blarina brevicauda

Type  Native peptide

Classification

  

Active ACP TRPV6 antagonists



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma ~18%Inhibition=100 µM Promega CellTiter Blue assay 72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  SOR-C13 and SOR-C27, derived from the C-terminus of soricidin, are high-affinity antagonists of human TRPV6 channels that are up-regulated in a number of cancers

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02006

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C72H116N20O19

Absent amino acids  ACGIMNQTWY

Common amino acids  KLP

Mass  178005

Pl  9.54

Basic residues  4

Acidic residues  2

Hydrophobic residues  4

Net charge  2

Boman Index  -3275

Hydrophobicity  -91.54

Aliphatic Index  82.31

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23554944

Title  In Vivo Detection of Human TRPV6-Rich Tumors with Anti-Cancer Peptides Derived from Soricidin

Doi 10.1371/journal.pone.0058866

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.